DK1185264T3 - Fremgangsmåde til fremstilling af amorft atorvastatin-calcium - Google Patents
Fremgangsmåde til fremstilling af amorft atorvastatin-calciumInfo
- Publication number
- DK1185264T3 DK1185264T3 DK00900300T DK00900300T DK1185264T3 DK 1185264 T3 DK1185264 T3 DK 1185264T3 DK 00900300 T DK00900300 T DK 00900300T DK 00900300 T DK00900300 T DK 00900300T DK 1185264 T3 DK1185264 T3 DK 1185264T3
- Authority
- DK
- Denmark
- Prior art keywords
- atorvastatin calcium
- preparation
- solvent
- amorphous atorvastatin
- amorphous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN775DE1999 IN191236B (de) | 1999-05-25 | 1999-05-25 | |
PCT/IB2000/000014 WO2000071116A1 (en) | 1999-05-25 | 2000-01-06 | Process for the production of amorphous atorvastatin calcium |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1185264T3 true DK1185264T3 (da) | 2007-08-20 |
Family
ID=11091180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00900300T DK1185264T3 (da) | 1999-05-25 | 2000-01-06 | Fremgangsmåde til fremstilling af amorft atorvastatin-calcium |
Country Status (15)
Country | Link |
---|---|
US (2) | US6528660B1 (de) |
EP (1) | EP1185264B1 (de) |
CN (2) | CN1196679C (de) |
AT (1) | ATE362759T1 (de) |
AU (1) | AU778962B2 (de) |
BR (1) | BR0010923A (de) |
DE (1) | DE60034946T2 (de) |
DK (1) | DK1185264T3 (de) |
ES (1) | ES2284472T3 (de) |
HK (1) | HK1045118A1 (de) |
IN (1) | IN191236B (de) |
MY (1) | MY133511A (de) |
PT (1) | PT1185264E (de) |
WO (1) | WO2000071116A1 (de) |
ZA (1) | ZA200109656B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
SI20814A (sl) * | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
IN190564B (de) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
PL367943A1 (en) * | 2001-06-29 | 2005-03-07 | Warner-Lambert Company Llc | Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA2456095C (en) | 2001-08-31 | 2010-05-11 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
EP1615884B1 (de) * | 2003-04-11 | 2016-06-29 | LEK Pharmaceuticals d.d. | Verfahren zur herstellung von amorphem calcium atorvastatin |
AU2004234057A1 (en) * | 2003-04-29 | 2004-11-11 | Akzo Nobel N.V. | Antisolvent solidification process |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
US7241800B2 (en) * | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
CN1942439B (zh) | 2004-03-17 | 2011-12-21 | 兰贝克赛实验室有限公司 | 无定形形式的阿托伐他汀钙的制备方法 |
CN1960972A (zh) * | 2004-04-16 | 2007-05-09 | 辉瑞产品公司 | 用于形成无定形阿托伐它汀钙的方法 |
JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
WO2006008091A2 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
EP1771412A2 (de) * | 2004-07-20 | 2007-04-11 | Warner-Lambert Company LLC | Kristalline formen von [r-(r*)]-2-(4-fluorphenyl)-beta,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-calciumsalz (2:1) |
EP1784389A4 (de) | 2004-08-27 | 2009-03-25 | Biocon Ltd | Verfahren zur herstellung von amorphem atorvastatin-calcium |
KR20090033405A (ko) * | 2004-10-18 | 2009-04-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법 |
EP1807055A1 (de) * | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Verfahren zur herstellung von amorphem atorvastatin |
WO2006048888A1 (en) * | 2004-11-01 | 2006-05-11 | Jubilant Organosys Limited | Novel process for the preparation of amorphous atorvastatin calcium salt |
AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
WO2007052296A2 (en) * | 2005-08-23 | 2007-05-10 | Kopran Research Laboratories Ltd | A process of preparing amorphous atorvastatin calcium |
US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
US8084488B2 (en) | 2005-11-21 | 2011-12-27 | Pfizer Inc. | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium |
EP1810667A1 (de) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin |
US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
WO2009016358A2 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
EP2075246A1 (de) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz |
CN101684090B (zh) * | 2008-09-27 | 2012-12-05 | 广东东阳光药业有限公司 | 一种制备无定形阿托伐他汀钙的方法 |
US8115015B2 (en) | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
US10138206B2 (en) * | 2014-10-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU44680B (en) | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
DE69616808T2 (de) * | 1995-07-17 | 2002-05-29 | Warner Lambert Co | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin) |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
-
1999
- 1999-05-25 IN IN775DE1999 patent/IN191236B/en unknown
-
2000
- 2000-01-06 DE DE60034946T patent/DE60034946T2/de not_active Expired - Lifetime
- 2000-01-06 PT PT00900300T patent/PT1185264E/pt unknown
- 2000-01-06 CN CNB008080275A patent/CN1196679C/zh not_active Expired - Fee Related
- 2000-01-06 CN CNA2005100525833A patent/CN1680315A/zh active Pending
- 2000-01-06 BR BR0010923-1A patent/BR0010923A/pt not_active IP Right Cessation
- 2000-01-06 WO PCT/IB2000/000014 patent/WO2000071116A1/en active IP Right Grant
- 2000-01-06 US US09/979,475 patent/US6528660B1/en not_active Expired - Lifetime
- 2000-01-06 ES ES00900300T patent/ES2284472T3/es not_active Expired - Lifetime
- 2000-01-06 AT AT00900300T patent/ATE362759T1/de active
- 2000-01-06 EP EP00900300A patent/EP1185264B1/de not_active Expired - Lifetime
- 2000-01-06 AU AU19967/00A patent/AU778962B2/en not_active Ceased
- 2000-01-06 DK DK00900300T patent/DK1185264T3/da active
- 2000-05-24 MY MYPI20002283A patent/MY133511A/en unknown
-
2001
- 2001-11-23 ZA ZA200109656A patent/ZA200109656B/en unknown
-
2002
- 2002-09-12 HK HK02106699.9A patent/HK1045118A1/zh unknown
-
2003
- 2003-03-03 US US10/378,574 patent/US20030149279A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR0010923A (pt) | 2002-07-16 |
EP1185264A1 (de) | 2002-03-13 |
DE60034946D1 (de) | 2007-07-05 |
ATE362759T1 (de) | 2007-06-15 |
HK1045118A1 (zh) | 2002-11-15 |
CN1351493A (zh) | 2002-05-29 |
ES2284472T3 (es) | 2007-11-16 |
MY133511A (en) | 2007-11-30 |
US6528660B1 (en) | 2003-03-04 |
AU778962B2 (en) | 2004-12-23 |
CN1196679C (zh) | 2005-04-13 |
PT1185264E (pt) | 2007-07-10 |
US20030149279A1 (en) | 2003-08-07 |
IN191236B (de) | 2003-10-11 |
ZA200109656B (en) | 2002-06-27 |
DE60034946T2 (de) | 2008-01-17 |
WO2000071116A1 (en) | 2000-11-30 |
EP1185264B1 (de) | 2007-05-23 |
AU1996700A (en) | 2000-12-12 |
CN1680315A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1185264T3 (da) | Fremgangsmåde til fremstilling af amorft atorvastatin-calcium | |
DK1161426T3 (da) | Fremgangsmåde til fremstilling af furfural | |
WO2005104711A8 (en) | Purification of progesterone receptor modulators | |
DK1183261T3 (da) | Fremgangsmåde til separering af analoge organiske forbindelser | |
CA2067711A1 (en) | Solid phase extraction purification of dna | |
IS4872A (is) | Aðferð til að framleiða magnesíumsalt af útskiptum súlfínýl-heteróhring | |
DK1181272T3 (da) | Fremgangsmåde til fremstilling af rent citalopram | |
DK1181713T3 (da) | Fremgangsmåde til fremstilling af rent citalopram | |
DK0937068T3 (da) | Fremgangsmåde til krystallisation af losartan | |
DK1349580T4 (da) | Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning | |
MXPA04005603A (es) | Sal cristalina de calcio del acido (r-(r*, r*) (-2- (4-fluorofenil)- (,(- dihidroxi- 5(1- metiletil)- 3-fenil -4-((fenilamino) carbonil (-1h-pirrol -heptanoico (2:1). | |
DE60003137D1 (de) | Verfahren zu Rückgewinnung von N-Vinyl-2-Pyrrolidon | |
BR0114797B1 (pt) | método para a remoção de água de um composto de organoborano úmido. | |
DE69927044D1 (de) | Verfahren zur racemizierung | |
DK1206452T3 (da) | Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser | |
WO2007017244A3 (en) | A PROCESS FOR THE PURIFICATION OF SUBSTITUTED 2-(2-PYRIDYLMETHYL)SULFINYL-lH-BENZIMIDAZOLE COMPOUNDS BY PRECIPITATION IN THE PRESENCE OF A QUATERNARY AMMONIUM SALT | |
DK1214321T3 (da) | Proces til fremstilling af naphthyridin-3-carboxylsyre-derivater | |
DE60002020D1 (de) | Verfahren zur Herstellen von hochreinem Xylitol | |
FR2801306B1 (fr) | Procede de purification des monomeres (meth) acryliques par distillation | |
DE60016813D1 (de) | Verfahren zur Reinigung einer Polycarbonatlösung | |
DK1177164T3 (da) | Fremgangsmåde til oprensning af diacerein | |
DK1328357T3 (da) | Fremgangsmåde til behandling af slagge fra affaldsforbrændingsanlæg | |
DK0965586T3 (da) | Fremgangsmåde til oprensning af carbazolesterforstadier til 6-chlor-alfa-methyl-carbazol-2-eddikesyre | |
DE50008776D1 (de) | Verfahren zur gewinnung von bakteriorhodopsin | |
DK1029867T3 (da) | Fremgangsmåde til fremstilling af organiske azider |